Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Summary

This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects received BAF312 treatment.

Timeline

Start

2010-06-15

Primary completion

2012-06-13

Completion

2012-06-13

Drugs

Indications